Testing version — LOERadar is in active testing. Features and data may change.
ORZEYFUL (OVEPOREXTON) | LOERadar
Not in the current Orange Book — This application is not listed in FDA's current Orange Book data files (no listed patents or exclusivities). Product and approval data shown are from FDA's Drugs@FDA database.
ORZEYFUL
NDANot in Orange Book
OVEPOREXTON | N220860 | TAKEDA PHARMS USA
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (3)
Sort:
#001 — .05MG
▴
TABLET; ORAL | Approved: Aug. 5, 2026
No patent or exclusivity listings for this strength.